HERTHENA-Lung01: A Phase II Study of Patritumab Deruxtecan (HER3-DXd) in Previously Treated Metastatic <i>EGFR</i> -mutated NSCLC

DOI オープンアクセス

この論文をさがす

説明

Antibody–drug conjugate; Non-small-cell lung cancer; Patritumab deruxtecan Conjugat anticossos-fàrmac; Càncer de pulmó de cèl·lules no petites; Patritumab deruxtecan Conjugado anticuerpo-fármaco; Cáncer de pulmón de células no pequeñas; Patritumab deruxtecan Limited treatment options exist for EGFR-mutated NSCLC that has progressed after EGFR TKI and platinum-based chemotherapy. HER3 is highly expressed in EGFR-mutated NSCLC, and its expression is associated with poor prognosis in some patients. Patritumab deruxtecan (HER3-DXd) is an investigational, potential first-in-class, HER3-directed antibody–drug conjugate consisting of a HER3 antibody attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. In an ongoing phase I study, HER3-DXd demonstrated promising antitumor activity and a tolerable safety profile in patients with EGFR-mutated NSCLC, with or without identified EGFR TKI resistance mechanisms, providing proof of concept of HER3-DXd. HERTHENA-Lung01 is a global, registrational, phase II trial further evaluating HER3-DXd in previously treated advanced EGFR-mutated NSCLC.

収録刊行物

  • Future Oncology

    Future Oncology 19 1319-1329, 2023-05-22

    Informa UK Limited

詳細情報 詳細情報について

  • CRID
    1870584741587715840
  • DOI
    10.2217/fon-2022-1250
  • ISSN
    17448301
    14796694
  • データソース種別
    • OpenAIRE

問題の指摘

ページトップへ